Does aging do something to time so it seems like as you get older that time goes by faster? Remember as a little kid when summer seemed to last forever and car rides could be agonizingly long? I’ve heard two theories on this. One is that the brain’s baseline of activity slows down with aging […]
Weekly stem cell reads: aging & cells, iPS cell mutations, gut, more Read More »
I took a cross-country road trip earlier this month that was pretty amazing and barely thought about stem cell research for the first time in years. We did run across one stem cell clinic in Florida by accident. I’ll write about that trip soon, but first we have our weekly reads including some very cool
Weekly stem cell reads: space, plagiarism, HIV, diabetes, more Read More »
When I’m asked about the most promising areas of stem cell clinical research, cell therapy for type I diabetes is near the top including work by a biotech called ViaCyte. Other firms are in the mix too, boosting the overall odds of success in the coming decade. It’s really that promising even though there are
ViaCyte purchase puts Vertex in driver’s seat on stem cells for diabetes Read More »
I’ve been following the stem cells for COVID arena for more than two years. During this time researchers have launched scores of trials. A few have been published including a new one. It’s been a wild ride that at times has included politics and an odd cast of characters. There was Rick Perry and also Rudy Guiliani getting
A close look at new stem cells for COVID trial pub Read More »
Cloning is one of those topics that both fascinates and kind of scares people, especially the idea of duplicating people. I regularly cover the topic here on The Niche because stem cell technologies are involved. Also, one form of the process sometimes called “therapeutic cloning” involves embryonic stem cells. Duplicating mammals has now long been
Weekly reads: freeze-dried cloning, FDA signals, stem cell escapees Read More »
Some unproven stem cell clinics like one called Giostar have multiple locations sprouting up. To me the concern with that spreading is the potential of multiplying risks to consumers. It can be hard to get a clear take on what these clinics are doing too. What’s in this article What is Giostar? | Giostar review |
Giostar stem cell clinic chain review, red flags, & lawsuit Read More »
The FDA stem cell clinic problem just continues to grow, while the agency has been oddly quiet in this space for more than a year. It’s been a major disappointment, particularly as in recent years FDA leadership had implied that bold action was coming. Their own words spiked expectations that the agency would tackle unproven
Did COVID derail FDA stem cell clinic plan? Read More »
When I first started this blog back in 2010 the most contentious issue on the more political side of our field was federal funding for embryonic stem cell research. It was something you couldn’t take for granted. Some history on embryonic stem cell funding in the US There were times back then when funding of
Is embryonic stem cell research a target after Roe? Read More »
Dr. Paolo Macchiarini exemplifies how things can change quickly in the stem cell world and go from sky highs to deep lows. Stem cell rollercoasters Over the years, a few academic stem cell researchers as well as some operators in the unproven clinic sphere have had dizzying ups and downs. There’s John Kosolcharoen. His company
Paolo Macchiarini guilty in criminal stem cell case but does a Houdini again Read More »
I recently wrote about stem cell-related ideas for anti-aging and even cheating death, but there are of course other approaches including drugs like metformin. A new article outlines a massive research funding plan to tackle aging. Let’s start with that. Recommend reads including anti-aging Saudi Arabia plans to spend $1 billion a year discovering treatments to
Weekly reads: $1B Saudi anti-aging push, OCT4 necklace, cancer trial wows, coffee brain Read More »